Fraud's not that big of a deal: the Valeant story, according to Bill Ackman

FierceBiotech Radio

Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shire's up-and-down efforts to buy stuff it wants.